Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baitouweng Decoction via TET for Ulcerative Colitis
NCT06421818Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanjing Medical University
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Baitouweng Tang in ulcerative colitis (UC) (4 arms), sponsored by The Second Affiliated Hospital of Nanjing Medical University. Primary endpoint: Concentration of fecal calprotectin at Day 53. Started May 2024; status: recruiting.
02
Drugs
Baitouweng Tang
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06421818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06421818.